Clinical trials: Bone Tumour
Bone Cysts
Aneurysmal Bone Cyst Imaging After Interventional Radiology Treatment
This study aims to describe the clinical outcomeand the radiological appearance of aneurysmal bone cyst treated by means of interventional radiology procedures (percutaneous sclerosis and endovascular embolization)
- Trial name
- KOA-RI (NCT05075148)
- Testing
- radiology
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Polycythemia Vera, Essential Thrombocythemia
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- MPN-K (NCT03745378)
- Testing
- JAK2V617F mutation
- Where
- 30 sites in Czechia, Germany and 4 more
- Volunteers
- 1,881 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea…
- Trial name
- FOND-O (NCT02635984)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Augusta University
Leukemia
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia…
- Trial name
- NCT00004933
- Testing
- hydroxyurea, Homoharringtonine
- Where
- 133 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Bone Neoplasm
Multicentric Bone Tumor Imaging Report and Data System
In this study a previously described structured multimodality image report system for the characterization of focal bone lesions is evaluated in a larger patient population.
- Trial name
- BTI-RADS M (NCT04884048)
- Testing
- Radiographs
- Where
- 9 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Central Hospital, Nancy, France
Myeloproliferative Neoplasm
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive.
- Trial name
- MPN-BIOCLOT (NCT04177576)
- Testing
- 2 additional tubes of blood
- Where
- 24 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Bordeaux
Gynecologic Cancer, Radiotherapy Side Effect
Bone Toxicity Following Pelvic Radiotherapy
A randomised controlled clinical feasibility trial to determine the feasibility and acceptability of a "musculoskeletal health package (MHP)" intervention in women undergoing pelvic radiotherapy for gynaecological malignancies…
- Conditions
- Gynecologic Cancer, Radiotherapy Side Effect, Fracture
- Trial name
- RadBone (NCT04555317)
- Testing
- Musculoskeletal health package
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- The Christie NHS Foundation Trust
Bone Neoplasms, Musculoskeletal Neoplasms
Predicting Allograft Volume in Orthopedic Oncology: Hemielipsoid Formula vs Intraoperative Fluid-Fill Measurement
Bone defects following primary musculoskeletal tumor resection are frequently reconstructed using structural allografts. Allograft availability is limited, and intraoperative waste due to oversized graft selection remains a…
- Conditions
- Bone Neoplasms, Musculoskeletal Neoplasms, Bone Transplantation
- Trial name
- PREDALL (NCT07653178)
- Testing
- Hemielipsoid Formula-Based Preoperative and Intraoperative Bone Defect Volume Estimation
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Sakarya University
Leukemia, Lymphoma
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
RATIONALE: Giving total-body irradiation and chemotherapy, such as cyclophosphamide, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00317785
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03709550
- Testing
- Decitabine, Enzalutamide
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Bone Metastases, Metastatic Solid Tumor
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
This is a prospective, randomized, single-center clinical trial evaluating whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related…
- Trial name
- pRevenT (NCT07540650)
- Testing
- Prophylactic External Beam Radiotherapy, Standard of Care
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- Institute of Oncology Ljubljana
Myeloproliferative Disorders, Myelofibrosis
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus…
- Conditions
- Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
- Trial name
- INDEPENDENCE (NCT04717414)
- Testing
- ACE-536
- Where
- 185 sites in United States, Argentina and 24 more
- Volunteers
- 313 people
- Sponsor
- Celgene
Breast Cancer, Breast Cancer Survivors
Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy
Breast cancer survivors receiving endocrine (hormonal) therapy (aromatase inhibitors) are at high risk for cancer treatment-induced bone loss and osteoporosis due to estrogen depletion.
- Conditions
- Breast Cancer, Breast Cancer Survivors, Aromatase Inhibitors, Osteoporosis or Osteopenia
- Trial name
- PilatesBCS2026 (NCT07334626)
- Testing
- Pilates Exercises, Calcium and Vitamin D Supplementation
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Benha University
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Ewing's Sarcoma
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
A two-part trial in patients with metastic Ewing's sarcoma. Participants in Part 1 will be randomized to receive either Vigil immunotherapy or gemcitabine and docetaxel with the objective of comparing the overall survival between…
- Trial name
- NCT02511132
- Testing
- Vigil, Temozolomide, Irinotecan
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gradalis, Inc.
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05823714
- Testing
- VEN+AZA+Modified BUCY
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04893915
- Testing
- Cytokine-induced memory-like NK cells, Fludarabine, Cyclophosphamide
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies the side effects and best dose of bortezomib when given together with daunorubicin and cytarabine and to see how well it works in treating older patients with previously untreated acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00742625
- Testing
- daunorubicin hydrochloride, cytarabine, bortezomib
- Where
- 22 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01005368
- Testing
- fluorescence in situ hybridization, mutation analysis, nucleic acid sequencing
- Where
- 35 sites in United States
- Volunteers
- 600 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.